FDA Approves Remdesivir To Treat Children With COVID-19
The FDA announced Monday that it approved use of the antiviral medication to treat patients as young as 28 days old.
LEARN MOREPosted: 1:34 p.m. EDT Apr 28, 2022
Moderna is seeking to be the first to offer COVID-19 vaccine for the youngest American children, as it asked the Food and Drug Administration Thursday to clear low-dose shots for babies, toddlers and preschoolers.
Frustrated families are waiting impatiently for a chance to protect the nation’s littlest kids as all around them people shed masks and other public health precautions -- even though highly contagious coronavirus mutants continue to spread. Already about three-quarters of children of all ages show signs they've been infected at some point during the pandemic.
Moderna submitted data to the Food and Drug Administration that it hopes will prove two low-dose shots can protect children younger than 6 -- although the effectiveness wasn't nearly as high in kids tested during the Omicron surge as earlier in the pandemic.
Moderna said two kid doses were about 40% to 50% effective at preventing symptomatic COVID-19, not a home run but for many parents, any protection would be better than none.
Now, only children ages 5 or older can be vaccinated in the U.S., using rival Pfizer’s vaccine, leaving 18 million younger tots unprotected.
Moderna's vaccine isn't the only one in the race. Pfizer is soon expected to announce if three of its even smaller-dose shots work for the littlest kids, months after the disappointing discovery that two doses weren’t quite strong enough.
Whether it’s one company’s shots or both, FDA vaccine chief Dr. Peter Marks said the agency will “move quickly without sacrificing our standards” in deciding if tot-sized doses are safe and effective.
If FDA clears vaccinations for the littlest, next the Centers for Disease Control and Prevention would have to recommend who needs them -- all tots or just those at higher risk from COVID-19.
Additional reporting by The Associated Press.
